关于多巴胺受体agonists在不安腿综合征的机制
Sergi Ferré1, Diego García-Borreguero2, Christopher J Earley3
1Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD.
Sleep
|September 29, 2025
概括
不安腿综合征 (RLS) 的多巴胺受体激动剂在不同的剂量中准不同的受体. 低剂量会影响前突触D2和D4受体产生治疗效果,而高剂量可能会激活后突触D1和D3受体,从而可能导致增强.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多巴胺D3受体 (D3R) 激动剂用于不安腿综合征 (RLS),D3R被认为是主要的治疗标.
- 治疗效应通常归因于D3R与其他D2类受体相比的优先结合亲和力.
研究的目的:
- 对RLS中多巴胺受体激动剂的药理学研究进行审查.
- 为了研究药理动力学和药理动力学因素的影响超越结合亲和力对受体向.
主要方法:
- 对最近的药理学研究进行了全面的审查.
- 对内在疗效,偏向性激动性,功能疗效,受体异构化和大脑透性的分析.
主要成果:
- 低剂量首选向多巴胺基神经元上的短D2受体 (D2SR) 和皮质底端的D2SR/D4受体.
- 较高剂量激活突触后条状D3受体,可能与D1受体形成异构体,与RLS增大有关.
- 考虑了脊柱D3受体在睡眠周期性腿部运动中的作用.
结论:
- 在RLS中多巴胺激动剂的治疗标是复杂的,涉及的因素超出了简单的结合亲和力.
- 前突触D2Rs和D4Rs是治疗效果的关键,而后突触D1Rs和D3Rs可能有助于增强.
- 了解这些细微差别可以为RLS提供更好的治疗策略.
相关概念视频
Restless Leg Syndrome and Night Terrors
487
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
487
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
Parkinson's Disease: Treatment
986
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
986
REM Sleep Behavior Disorder
1.4K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
1.4K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.5K
Sedatives and Hypnotics Drugs: Miscellaneous Agents
518
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
518


